This clinical trial focuses on patients who have undergone a kidney transplantation. The study involves a treatment called Idefirix, which contains the active substance imlifidase. Imlifidase is a protein that helps in preparing patients for kidney transplants by reducing certain antibodies that can cause complications. The trial includes two groups: patients who are highly sensitized, meaning they have a high level of antibodies that can make finding a compatible kidney difficult, and a reference group of less sensitized patients who received a compatible kidney transplant.
The purpose of the study is to observe the long-term outcomes of patients who received imlifidase before their kidney transplant. The study will follow these patients over several years to see how well their transplanted kidneys function and to monitor their overall health. This includes checking for any signs of the body rejecting the new kidney, which is known as graft failure, and assessing kidney function through tests like the estimated Glomerular Filtration Rate (eGFR), which measures how well the kidneys are filtering waste from the blood.
Participants in the study will be monitored for up to five years after their transplant. The study will also look at patient survival rates, the health of the transplanted kidney, and any side effects related to the imlifidase treatment. Additionally, the study will evaluate the patients’ ability to participate in social activities and their overall quality of life. This information will help doctors understand the long-term benefits and risks of using imlifidase in kidney transplant patients.
Austria 
Belgium 
Czechia 
France 
Italy 
Spain 
Sweden 
The Netherlands 
